Healthcare Sector
Market Tracker
15m Chart - Support and Resistance levels are based on the large dark pool & equity prints at the plotted levels. Displays strongest levels above and below the spot price.
Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.
Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.
Represents the largest cumulative premium levels above and below the current spot price. The price in the pink bubble represents the spot price.
Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.
Expires | Type | Strike | OI | Change | Percent |
---|---|---|---|---|---|
06/20/2025 | PUT | $5.00 | 1,106 | +100 | +9.94% |
03/21/2025 | PUT | $15.00 | 1,687 | +44 | +2.68% |
01/16/2026 | CALL | $17.50 | 516 | +40 | +8.40% |
03/21/2025 | CALL | $15.00 | 5,389 | +12 | +0.22% |
07/18/2025 | CALL | $17.50 | 413 | +9 | +2.23% |
07/18/2025 | CALL | $10.00 | 470 | +5 | +1.08% |
10/17/2025 | PUT | $25.00 | 0 | 0 | |
10/17/2025 | PUT | $30.00 | 0 | 0 | |
06/20/2025 | CALL | $15.00 | 5,863 | -5 | -0.09% |
04/17/2025 | CALL | $15.00 | 1,540 | -10 | -0.65% |
01/16/2026 | CALL | $10.00 | 1,713 | -25 | -1.44% |
01/16/2026 | CALL | $12.50 | 1,088 | -25 | -2.25% |
Contracts with largest changes in open interest from the previous trading day to the current/most recent.
Name | Pct Held | Shares | Total |
---|---|---|---|
SPDR (R) Ser Tr-SPDR� Kensho New Economies Composite ETF | 2.76% | 1.79M | 13.78M |
Vanguard Total Stock Market Index Fund | 2.37% | 1.53M | 11.81M |
iShares Russell 2000 ETF | 1.63% | 1.06M | 8.14M |
Vanguard Extended Market Index Fund | 1.06% | 683.23k | 5.27M |
Fidelity Small Cap Index Fund | 0.61% | 393.73k | 3.04M |
Invesco ETF Tr II-Invesco DWA Small Cap Momentum ETF | 0.42% | 273.91k | 2.11M |
Fidelity Extended Market Index Fund | 0.39% | 253.96k | 1.96M |
iShares Russell 2000 Growth ETF | 0.35% | 227.62k | 1.75M |
Russell Inv Co- Tax-Managed U.S. Mid & Small Cap Fund | 0.28% | 178.93k | 1.38M |
iShares Russell 2000 Value ETF | 0.26% | 169.92k | 1.31M |
Liquidia Corporation to Report Full Year 2024 Financial Results on March 19, 2025
03/12 08:00 am
GlobeNewswire Inc.
Read moreAtea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors
02/24 08:00 am
GlobeNewswire Inc.
Read moreEvolving Landscape of Cardiology Segment: Key Market Insights of Latest Published Rare Cardiovascular Diseases Report — Giant-Cell Arteritis, Pulmonary Arterial Hypertension, and Restrictive Cardiomyopathy | DelveInsight
01/14 02:00 pm
GlobeNewswire Inc.
Read moreUnited States Supreme Court Declines to Review Rulings that Invalidate United Therapeutics’ Patent
10/07 10:00 am
GlobeNewswire Inc.
Read moreLiquidia and Pharmosa Biopharm Expand Collaboration to Develop Sustained Release Inhaled Treprostinil (L606)
10/02 06:00 am
GlobeNewswire Inc.
Read moreU.S. FDA Grants Tentative Approval of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
08/19 06:00 am
GlobeNewswire Inc.
Read moreLiquidia corp chief medical officer sells $18.4k in stock - Investing.com
07/15 09:39 pm
Investing.com
Read moreLiquidia Corp executive sells over $14k in company stock - Investing.com
07/15 06:47 pm
Investing.com
Read moreForecasting The Future: 5 Analyst Projections For Liquidia
06/25 03:00 pm
Benzinga
Read moreLiquidia Announces Poster Presentations at the 7th World Symposia on Pulmonary Hypertension (WSPH)
06/18 08:42 am
GlobeNewswire Inc.
Read more7 Analysts Have This To Say About Liquidia
06/03 08:00 am
Benzinga
Read moreLiquidia Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)
05/15 08:01 am
Benzinga
Read moreDown -11.26% in 4 Weeks, Here's Why You Should You Buy the Dip in Liquidia Technologies (LQDA)
05/14 09:35 am
Zacks Investment Research
Read moreLiquidia Corporation Reports First Quarter 2024 Financial Results and Provides Corporate Update
05/13 05:43 pm
GlobeNewswire Inc.
Read moreDeciphera Pharmaceuticals, Inc. (DCPH) Reports Q1 Loss, Misses Revenue Estimates
05/10 08:50 am
Zacks Investment Research
Read moreLiquidia Announces Poster Presentation at the American Thoracic Society (ATS) 2024 International Conference on Its Open-Label Safety Study of L606 (Liposomal Treprostinil) in Patients with PAH and PH-ILD
05/10 08:00 am
GlobeNewswire Inc.
Read moreArvinas, Inc. (ARVN) Reports Q1 Loss, Lags Revenue Estimates
05/07 08:15 am
Zacks Investment Research
Read moreWill Editas Medicine (EDIT) Report Negative Q1 Earnings? What You Should Know
04/26 10:00 am
Zacks Investment Research
Read moreEarnings Preview: Liquidia Technologies, Inc. (LQDA) Q1 Earnings Expected to Decline
04/25 10:02 am
Zacks Investment Research
Read moreLiquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare Conference
04/02 09:00 am
GlobeNewswire Inc.
Read moreThe Analyst Landscape: 5 Takes On Liquidia
04/01 02:00 pm
Benzinga
Read moreUpdate on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder
04/01 06:00 am
GlobeNewswire Inc.
Read moreUnveiling 6 Analyst Insights On Liquidia
03/13 05:00 pm
Benzinga
Read moreLiquidia Technologies, Inc. (LQDA) Reports Q4 Loss, Lags Revenue Estimates
03/13 07:10 am
Zacks Investment Research
Read moreLiquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update
03/13 06:00 am
GlobeNewswire Inc.
Read moreArcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates
03/07 06:10 pm
Zacks Investment Research
Read moreEarnings Preview: Pliant Therapeutics, Inc. (PLRX) Q4 Earnings Expected to Decline
03/07 11:00 am
Zacks Investment Research
Read moreLiquidia Corporation to Report Full Year 2023 Financial Results on Wednesday, March 13, 2024
03/06 07:30 am
GlobeNewswire Inc.
Read moreArbutus Biopharma (ABUS) Reports Q4 Loss, Misses Revenue Estimates
02/29 09:40 am
Zacks Investment Research
Read moreArvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates
02/27 09:30 am
Zacks Investment Research
Read moreUnited Therapeutics (UTHR) Q4 Earnings & Sales Beat Estimates
02/22 01:22 pm
Zacks Investment Research
Read moreStrength Seen in AnaptysBio, Inc. (ANAB): Can Its 5.9% Jump Turn into More Strength?
02/19 06:54 am
Zacks Investment Research
Read moreThis United Therapeutics Analyst Is No Longer Bearish, Expects Mid-Decade $4B Revenue Run Rate
02/12 12:00 pm
Benzinga
Read moreLiquidia Corporation Announces Poster Presentation at the Pulmonary Vascular Research Institute 2024 Annual Congress
01/30 07:30 am
GlobeNewswire Inc.
Read moreWall Street Analysts Think Liquidia Technologies, Inc. (LQDA) Could Surge 71.41%: Read This Before Placing a Bet
01/29 10:55 am
Zacks Investment Research
Read moreLiquidia Corporation Provides Update on New Drug Application for YUTREPIA™ (treprostinil) inhalation powder
01/25 07:00 am
GlobeNewswire Inc.
Read moreLiquidia Corporation Announces Updates to Operations Leadership
01/19 07:30 am
GlobeNewswire Inc.
Read moreWall Street Analysts Believe Liquidia Technologies, Inc. (LQDA) Could Rally 29.94%: Here's is How to Trade
01/09 07:21 pm
Zacks Investment Research
Read moreWhat Makes Liquidia Technologies, Inc. (LQDA) a Strong Momentum Stock: Buy Now?
01/09 05:56 pm
Zacks Investment Research
Read moreLiquidia Corporation Files Response to United Therapeutics Lawsuit and Files Counterclaims
01/08 09:22 am
GlobeNewswire Inc.
Read moreDecoding 5 Analyst Evaluations For Liquidia
01/05 09:00 am
Benzinga
Read moreLiquidia Provides Update on Clinical Pipeline Targeting PAH and PH-ILD
01/05 07:45 am
GlobeNewswire Inc.
Read moreLiquidia Corporation Announces $100 Million in New Financings
01/04 10:10 am
GlobeNewswire Inc.
Read moreLiquidia Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
01/02 07:45 am
GlobeNewswire Inc.
Read more